Nxera Pharma Co., Ltd.
4565.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.51 | 0.01 | -7.30 | -4.57 |
| FCF Yield | -8.77% | -5.22% | 5.52% | 4.46% |
| EV / EBITDA | 1,234.90 | -24.91 | 38.70 | 56.54 |
| Quality | ||||
| ROIC | -3.95% | -4.37% | 1.04% | 17.99% |
| Gross Margin | 73.59% | 75.70% | 94.05% | 94.73% |
| Cash Conversion Ratio | 1.60 | 0.73 | 9.23 | 16.39 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.81% | -10.34% | 20.75% | 22.12% |
| Free Cash Flow Growth | -34.62% | -163.47% | 39.96% | 50.95% |
| Safety | ||||
| Net Debt / EBITDA | 339.35 | -4.36 | -10.32 | -14.08 |
| Interest Coverage | -6.93 | -3.82 | 3.72 | 1.82 |
| Efficiency | ||||
| Inventory Turnover | 0.86 | 1.07 | 28.94 | -28.27 |
| Cash Conversion Cycle | 314.12 | -13.00 | -571.37 | -428.92 |